Addition of ribociclib to firstline letrozole improves outcomes and maintains quality of life in postmenopausal women with HR+, HER2– advanced breast cancer, regardless of visceral metastases or dose intensity: Subgroup analyses from the MONALEESA-2 trialBack

To view this article, please confirm that you are a healthcare professional by clicking 'Confirm' below.